The effect of Taxol treatment on serum interleukln-8 (IL-8) levels in patients with ovarian carcinoma.

dc.contributor.authorUslu, R
dc.contributor.authorOzsaran, A
dc.contributor.authorSanli, UA
dc.contributor.authorDikmen, Y
dc.contributor.authorGoker, ENT
dc.contributor.authorGoker, E
dc.date.accessioned2019-10-27T18:24:42Z
dc.date.available2019-10-27T18:24:42Z
dc.date.issued1999
dc.departmentEge Üniversitesien_US
dc.identifier.endpage3808Sen_US
dc.identifier.issn1078-0432
dc.identifier.startpage3808Sen_US
dc.identifier.urihttps://hdl.handle.net/11454/36230
dc.identifier.volume5en_US
dc.identifier.wosWOS:000083945700393en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherAmer Assoc Cancer Researchen_US
dc.relation.ispartofClinical Cancer Researchen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleThe effect of Taxol treatment on serum interleukln-8 (IL-8) levels in patients with ovarian carcinoma.en_US
dc.typeConference Objecten_US

Dosyalar